$CYTH As with Underdog Pharmaceuticals, the similarities to this Australian company, Cholrem, are striking. It's almost as if the idea of using cyclodextrins to reduce cholesterol buildup was not so original after all. However, Scott and his team have one-upped the competition by conducting two trials simultaneously: patients receive the drug via intravenous application, while his investors get the enema-only version.
1 Like